Magazine

Table: A Rash of Symptoms


Long viewed by investors as a shelter from economic storms, the drug sector is suddenly exposed on all fronts

R&D SLOWDOWN

While the output from traditional drug discovery efforts has lagged, the payoff from new genomics-based technologies is taking longer than expected

PRICING PRESSURE

Political heat, plus pressure from managed-care companies and other big payers, will make it more difficult for drug companies to hike prices

ME-TOO COMPETITION

Copycat drugs appear on the market faster than ever, forcing drugmakers to increase marketing outlays in order to defend their big franchises

GENERIC HEADACHES

Over the next four years, drugs with a combined $30 billion in U.S. sales will lose patent protection or other forms of exclusivity, hurting revenues


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus